$31.60+0.01 (+0.03%)
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases.
Pharvaris N.V. in the Healthcare sector is trading at $31.60. Wall Street consensus targets $46.17 (13 analysts), implying a +46.1% move over the next 12 months. The stock is currently near its 52-week high of $33.33, remaining 21.0% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a...
Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions.
Pharvaris (NasdaqGS:PHVS) has completed a substantial equity offering to support late stage development of its lead treatment for hereditary angioedema. The company is preparing regulatory submissions, including a planned new drug application, and progressing Phase 3 trials for hereditary and acquired angioedema. This funding event comes as Pharvaris positions itself for potential commercialization of its lead product. Pharvaris enters this phase with its stock at $32.94 and a 3 year return...
This clinical-stage biotech, focused on rare disease therapies, reported a notable insider sale amid ongoing drug development milestones.
This biopharma innovator in rare disease therapies reported a notable insider sale amid a year of strong stock performance.
Shares of KalVista Pharmaceuticals catapulted Wednesday on a $1.9 billion takeover offer from Italy's Chiesi Group.